A novel β-sheet breaker, RS-0406, reverses amyloid β-induced cytotoxicity and impairment of long-term potentiation in vitro

British Journal of Pharmacology

Volumn 137, Issue 5, 2002, Pages 676-682

  Nakagami, Yasuhiro ^a   Nishimura, Satoko ^a   Murasugi, Takako ^a   Kaneko, Isao ^a   Meguro, Masaki ^a   Marumoto, Shinji ^a   Kogen, Hiroshi ^a   Koyama, Kazuo ^a   Oda, Tomiichiro ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide; Alzheimer's disease; Amyloid ; Fibrillogenesis; Hippocampus; Long term potentiation; sheet breaker

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; N,N' BIS(3 HYDROXYPHENYL)PYRIDAZINE 3,6 DIAMINE; RS 0406; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BETA SHEET; CONTROLLED STUDY; CYTOTOXICITY; ELECTROPHYSIOLOGY; FIBER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; LONG TERM POTENTIATION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN STABILITY; RAT; STATISTICAL ANALYSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CELLS, CULTURED; DIAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; LONG-TERM POTENTIATION; NEURONS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; PYRIDAZINES; RATS; RATS, WISTAR;

EID: 0036848056     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704911     Document Type: Article

References (24)

1. Anderton, B.H., Callahan, L., Coleman, P., Davies, P., Flood, D., Jicha, G.A., Ohm, T. & Weaver, C. (1998). Dendritic changes in Alzheimer's disease and factors that may underlie these changes. Prog. Neurobiol., 55, 595-609.
2. El-Agnaf, O.M., Irvine, G.B. & Guthrie, D.J. (1997). Conformations of β-amyloid in solution. J. Neurochem., 68, 437-439.
3. Emre, M., Geula, C., Ransil, B.J. & Mesulam, M.M. (1992). The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected β-amyloid in the rat brain. Neurobiol. Aging, 13, 553-559.
4. Esler, W.P., Stimson, E.R., Mantyh, P.W. & Maggio, J.E. (1999). Deposition of soluble amyloid-β onto amyloid templates: With application for the identification of amyloid fibril extension inhibitors. Methods Enzymol., 309, 350-374.
5. Findeis, M.A. & Molineaux, S.M. (1999). Design and testing of inhibitors of fibril formation. Methods Enzymol., 309, 476-488.
6. Grundman, M. & Thal, L.J. (2000). Treatment of Alzheimer's disease: Rationale and strategies. Neurol. Clin., 18, 807-828.
7. Iwai, T. & Oka, J. (2000). Blockade of LTP in the rat CA1 in vitro by β-amyloid protein (1-42): A role of endogenous GLP-1. Jpn. J. Pharmacol., 82 (Suppl 1): 236.
8. Kaneko, I., Yamada, N., Sakuraba, Y., Kamenosono, M. & Tutumi, S. (1995). Suppression of mitochondrial succinate dehydrogenase, a primary target of β-amyloid, and its derivative racemized at Ser residue. J. Neurochem., 65, 2585-2593.
9. Klein, W.L., Kraft, G.A. & Finch, C.E. (2001). Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci., 24, 219-224.
10. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A., 95, 6448-6453.
11. Levine, H. & Scholten, J.D. (1999). Screening for pharmacologic inhibitors of amyloid fibril formation. Methods Enzymol., 309, 467-476.
12. Liu, Y., Peterson, D.A., Kimura, H. & Schubert, D. (1997). Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) reduction. J. Neurochem., 69, 581-593.
13. Malinow, R., Mainen, Z.F. & Hayashi, Y. (2000). LTP mechanisms: From silence to four-lane traffic. Curr. Opin. Neurobiol., 10, 352-357.
14. McCurley, D., Castillo, G.M. & Snow, A.D. (1998). Therapeutic implications of PTI-00703: A natural plant extract that is a potent dissolver of Alzheimer's disease amyloid. Neurobiol. Aging, 19 (Suppl 4): 1070.
15. Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C.V., Checler, F., Godaux, E., Cordell, B. & van Leuven, F. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem., 274, 6483-6492.
16. 1-42-induced impairment of long-term potentiation in rat hippocampal slices. Jpn. J. Pharmacol., 88, 223-226.
17. Nakagami, Y., Saito, H. & Matsuki, N. (1997). Optical dye recording of trisynaptic pathway in rat hippocampal slices with a voltage-sensitive dye. Neuroscience, 81, 1-8.
18. Nicoll, R.A. & Malenka, R.C. (1995). Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature, 377, 115-118.
19. Pike, C.J., Burdick, D., Walencewicz, A.J., Glabe, C.G. & Cotman, C.W. (1993). Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci., 13, 1676-1687.
20. Poduslo, J.F., Curran, G.L., Kumar, A., Frangione, B. & Soto, C. (1999). β-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J. Neurobiol., 39, 371-382.
21. Selkoe, D.J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev., 81, 741-766.
22. Soto, C., Sigurdsson, E.M., Morelli, L., Kumar, R.A., Castano, E.M. & Frangione, B. (1998). β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat. Med., 4, 822-826.
23. Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condron, M.M., Lomakin, A., Benedek, G.B., Selkoe, D.J. & Teplow, D.B. (1999). Amyloid β-protein fibrillogenesis. J. Biol. Chem., 274, 25945-25952.
24. Yankner, B.A., Duffy, L.K. & Kirschner, D.A. (1990). Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides. Science, 250, 279-282.